Tuesday, 22 June 2010

GW Pharmaceuticals cannabis-based drug Sativex approved

From the MS Trust webiste: 

The cannabis-based mouth spray, Sativex, has received approval from the UK drug' regulator (MHRA) as an add-on treatment for MS related spasticity. Sativex receives its UK licence as an add-on treatment for moderate to severe MS spasticity in people who receive inadequate relief from the standard oral anti-spasticity medicines or have experienced unbearable side effects whilst taking these medicines. Read article here